Skip to content
RDL Network logo
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial — Christian U. Blank (2025) | RDL Network